Yenilikçi İlaçlar İnisiyatifi (IMI) IMI2- 13. Çağrısı açılmıştır.
İlk aşama başvurular için son tarih: 28 Şubat 2018
İkinci aşama başvurular için son tarih: 6 Eylül 2018
Başvurular elektronik olarak H2020 kullanıcı portal üzerinden sunulmaktadır.
Detaylı bilgi için: https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2017-13-two-stage.html
Yeni bir IMI projesinde yer almak ya da proje başvurusunda bulunmak istiyorsanız, bir konsorsiyum bulmanız ya da oluşturmanız gerekmektedir.
https://www.imi.europa.eu/content/partner-search sayfası bu konuda yönlendirici bilgiler sunmaktadır.
Açık olan çağrı başlıkları listesi:
• IMI2-2017-13-01: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
• IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease
• IMI2-2017-13-03: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
• IMI2-2017-13-04: Mitochondrial Dysfunction in Neurodegeneration
• IMI2-2017-13-05: Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
• IMI2-2017-13-06: A sustainable European induced pluripotent stem cell platform
• IMI2-2017-13-07: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
• IMI2-2017-13-08: Human Tumour Microenvironment Immunoprofiling
• IMI2-2017-13-09: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
• IMI2-2017-13-10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
• IMI2-2017-13-11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
• IMI2-2017-13-12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes
• IMI2-2017-13-13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases
• IMI2-2017-13-14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
• IMI2-2017-13-15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases